Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation
The cost-effectiveness of multigene panels was evenly poised at higher thresholds, even when accounting for treatment initiation. Health systems reimbursing multigene panels and expensive therapies may be confronted with a value tradeoff, in which there may be improved survival albeit with a modest change in cost-effectiveness.
Authors
- Deirdre Weymann (ORCID: https://orcid.org/0000-0002-3072-5657)
- Dean A. Regier (ORCID: https://orcid.org/0000-0001-8876-0511)
- Cheryl Ho (ORCID: https://orcid.org/0000-0002-5922-3984)
- Alison M. Weppler (ORCID: https://orcid.org/0000-0003-3769-490X)
- Samantha Pollard (ORCID: https://orcid.org/0000-0002-3070-2092)
- Timothy P. Hanna (ORCID: https://orcid.org/0000-0003-3228-6042)
- Emanuel Krebs (ORCID: https://orcid.org/0000-0002-6590-8728)
- Ian Bosdet (ORCID: https://orcid.org/0000-0003-4739-007X)
- Aly Karsan (ORCID: https://orcid.org/0000-0001-6753-892X)
Institutions
- University of British Columbia (CA)
- Fraser Health (CA)
- Simon Fraser University (CA)
- Queen's University (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1200/po-24-00631
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05